SIOUX FALLS, S.D., Feb. 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced Samuel J. Reich, the Company's Chairman and CEO, will present an overview of the Company at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024 at 1:20 PM EST.
During the presentation, Mr. Reich will highlight the latest developments from the Company's lead clinical program, SAB-142, a novel biologic being developed for delaying onset and progression of Type 1 diabetes in adults and children.
The presentation can be accessed live on February 13, 2024 at 1:20 PM EST at: https://wsw.com/webcast/oppenheimer33/sabs/2766194.
A recording of the webcast will be accessible through the "Events" section of the Company's website at https://ir.sab.bio/news-events/events.
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics (SAB) is a clinical-stage biopharmaceutical company focused on developing fully human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company's lead asset, SAB-142, targets type 1 diabetes (T1D) with a ...